Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 86 | SFEBES2022 | Next issue

Society for Endocrinology BES 2022

Harrogate, United Kingdom
14 Nov 2022 - 16 Nov 2022

Card image cap
SfE BES is returning to Harrogate in 2022. Join with endocrine specialists from across the UK and beyond for the Society for Endocrinology's flagship meeting.

ea0086op1.1 | Thyroid | SFEBES2022

The ‘real-world’ outcomes of immunosuppression for Graves’ orbitopathy (GO) in a single centre multi-ethnic cohort

Khalid Ali , Lee Vickie , Feeney Claire

Background: Success of GravesÂ’ orbitopathy (GO) immunosuppression treatment is highly variable; patients relapse and a debilitating residual disease burden often remains with current therapies. This study describes the outcomes of immunosuppression in a multi-ethnic GO cohort treated in accordance with pre-2021 European Group on GO (EUGOGO) guidelines with first-line intravenous-methylprednisolone (IVMP). This study aims: (1) To evaluate the effect of first-line and addit...

ea0086op1.2 | Thyroid | SFEBES2022

Long-term mortality and cardiometabolic effects of treatment for hyperthyroidism: EGRET study

Torlinska Barbara , Hazlehurst Jonathan M. , Nirantharakumar Krishnarajah , Neil Thomas G. , Priestley Julia , Abrams Keith R. , Boelaert Kristien

Hyperthyroidism has been linked to long-term cardiovascular and metabolic morbidity and increased mortality. We aimed to assess differences in mortality and cardiometabolic outcomes depending on treatment modality to better inform patient-clinician decision-making.Methods: We identified 62,474 patients with newly diagnosed hyperthyroidism, treated with antithyroid drugs (ATD), radioiodine or thyroidectomy from a UK population-based GP database (>16M ...

ea0086op1.3 | Thyroid | SFEBES2022

Levothyroxine absorption test: a therapeutic strategy for improving medication adherence

Hossen Salman , Guma Muna , James Andy , Perros Petros , Mamoojee (on behalf of the RVI Endocrine Group) Yaasir

Introduction: Low adherence to levothyroxine replacement therapy can be up to 27% in some population. Suboptimal levothyroxine replacement in the community is primarily due to medication non-adherence. The Levothyroxine Absorption Test (LAT) is a well-described intervention at confirming medication non-adherence or malabsorption. We audited the short-term and long-term clinical outcomes of patients undergoing LAT at our Centre since 2016.Methods: LAT: Pa...

ea0086op1.4 | Thyroid | SFEBES2022

The role of oxidative stress in differentiated thyroid cancer risk stratification

Buczyńska Angelika , Sidorkiewicz Iwona , Kościuszko Maria , Adamska Agnieszka , Siewko Katarzyna , Jacek Krętowski Adam , Popławska-Kita Anna

Differentiated thyroid cancer (DTC) is the most common malignant neoplasm arising from the thyroid parenchymal cells. DTC risk stratification is a multi-stage process based on investigated histopathological features and ultrasound test outcomes combined with biochemical test results. Thus, searching for novel diagnostic indicators useful in cancer risk stratification are still needed. Recent studies revealed that oxidative and epigenetic alterations in DTC represent the signat...